Abstract | PURPOSE: METHODS: Retrospective consecutive case series. The charts of subjects treated with intravitreal bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen over a 12-month period were reviewed. The key variables explored were patient age, phakic status, posterior vitreous detachment status, baseline best-corrected visual acuity (BCVA), baseline central macular thickness (CMT), and type of chorodial neovascularization. The primary outcome measures were improvement in BCVA of 3 logMAR lines or more, maintenance of BCVA within 3 logMAR lines of baseline, number of intravitreal injections delivered over a 12-month period, and final CMT on optical coherence tomography. RESULTS: A total of 230 eyes met the criteria. Mean presenting BCVA was Snellen 20/55 (0.44 logMAR) and mean final BCVA was Snellen 20/44 (0.35 logMAR) (P < 0.001). A total of 23.5% (95% confidence interval [CI], 18.5-29.4%) of the subjects demonstrated an improvement in BCVA of 3 or more logMAR lines, whereas 96.5% (95% CI, 93.3-98.2%) of the subjects lost fewer than 3 logMAR lines. Mean CMT on optical coherence tomography changed from a baseline average of 373.1 μm (95%CI, 360.3-386.1 μm) to a final average of 305.5 μm (95% CI, 290.0-316.0 μm). The average number of injections during the 12-month period was 9.2 (95% CI, 9.0-9.4). Posterior vitreous detachment was associated with fewer injections on univariate and multivariate analysis (8.7 injections in the posterior vitreous detachment group versus 9.8 in the non- posterior vitreous detachment group, P < 0.001). Patients with poorer presenting BCVA and greater baseline CMTs were more likely to demonstrate a 3 or more logMAR line improvement in BCVA. Thinner final CMTs were independently associated with thinner presenting CMTs and fewer injections. CONCLUSION:
|
Authors | Ryan B Rush, Matthew P Simunovic, Lorelei Vandiver, Antonio V Aragon 2nd, Jason E Ysasaga |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 34
Issue 5
Pg. 846-52
(May 2014)
ISSN: 1539-2864 [Electronic] United States |
PMID | 24240560
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Coloring Agents
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Bevacizumab
- Indocyanine Green
|
Topics |
- Age Factors
- Aged
- Angiogenesis Inhibitors
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal, Humanized
(administration & dosage, therapeutic use)
- Bevacizumab
- Coloring Agents
- Female
- Fluorescein Angiography
- Humans
- Indocyanine Green
- Intravitreal Injections
- Male
- Retina
(pathology)
- Retrospective Studies
- Risk Factors
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(physiology)
- Vitreous Detachment
(diagnosis)
- Wet Macular Degeneration
(diagnosis, drug therapy)
|